A new version of the protocol has been adopted, according to which, in August 2023, the recruitment of patients who have undergone tuberculosis will begin to participate in the study of the GamTBVac vaccine for the prevention of relapse. We invite participants to the preliminary selection. Write to us 8 (993) 202 7840